Headlands Technologies LLC Invests $90,000 in Kodiak Sciences Inc. (NASDAQ:KOD)

Headlands Technologies LLC bought a new stake in Kodiak Sciences Inc. (NASDAQ:KOD) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 9,070 shares of the company’s stock, valued at approximately $90,000.

Other institutional investors have also modified their holdings of the company. PNC Financial Services Group Inc. boosted its stake in Kodiak Sciences by 1,501.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company’s stock worth $32,000 after purchasing an additional 2,988 shares during the period. US Bancorp DE acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth about $40,000. JPMorgan Chase & Co. grew its holdings in shares of Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after buying an additional 30,735 shares during the last quarter. Fox Run Management L.L.C. acquired a new position in Kodiak Sciences in the 4th quarter valued at about $118,000. Finally, SG Americas Securities LLC raised its stake in Kodiak Sciences by 61.4% during the 4th quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock valued at $206,000 after acquiring an additional 7,871 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Trading Down 2.1 %

Shares of KOD opened at $2.35 on Monday. The stock’s 50 day moving average is $4.32 and its two-hundred day moving average is $5.44. Kodiak Sciences Inc. has a twelve month low of $2.10 and a twelve month high of $11.60. The firm has a market capitalization of $123.96 million, a PE ratio of -0.64 and a beta of 2.40.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. On average, sell-side analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Analysts Set New Price Targets

KOD has been the topic of several analyst reports. Jefferies Financial Group upgraded Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Monday, December 9th. HC Wainwright reiterated a “neutral” rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research report on Monday, March 31st.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.